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Abstract
BACKGROUND: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are acute, life-threatening 
drug reactions, which lead to massive epidermal necrolysis. Granulysin plays an important role as a key mediator 
for keratinocyte apoptosis in these conditions. Erythema multiforme (EM) may have skin manifestation similar to 
SJS/TEN.
AIMS: The aim of the study was to compare serum granulysin levels in patients with SJS/TEN and EM as well as to 
investigate a possible association between serum granulysin levels and the severity of SJS/TEN.
METHODS: In total, 48 patients with SJS/TEN, 43 patients with EM, and 20 health controls (HCs) were enrolled. We 
measured serum granulysin levels using enzyme-linked immunosorbent assay.
RESULTS: The average level of serum granulysin in the SJS/TEN patients was 23.0 ng/ml (range 1.2–144.6 ng/ml), 
significantly higher than that of EM group (20.1 ng/ml; range 8.5–121 ng/ml, p < 0.05) and HCs group (20.8 ng/ml; 
range 10.1–46.7 ng/ml, p < 0.05). Of 48 SJS/TEN patients, the 25 samples collected <6 days after onset showed 
higher level of serum granulysin (27.7 ng/ml; range 2.5–144.6 ng/ml) than those collected ≥6 days after onset (17.9 
ng/ml; range 1.2–59 ng/ml; p > 0.05). No significant correlation was found between serum granulysin levels and the 
body surface area affected and the modified-SCORTEN. At the day of re-epithelialization, serum granulysin levels 
were not different compared with those at the day of hospitalization.
CONCLUSIONS: Serum granulysin levels are significantly higher in SJS/TEN group than in EM group. After the 
onset, serum granulysin levels in patients with SJS/TEN are not a good biomarker to evaluate the severity of the 
diseases.
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Introduction
Stevens-Johnson syndrome (SJS) and toxic 
epidermal necrolysis (TEN) are severe cutaneous 
adverse drug reactions (SCARs) characterized by 
extensive epidermal necrolysis, blisters, and skin 
sloughing [1], [2]. The most common causative drugs 
of SJS/TEN are carbamazepine, allopurinol, abacavir, 
phenytoin, and lamotrigine [1], [3], [4], [5]. The period 
between taking a drug and onset of symptoms ranges 
from a few days to 2 months [1], [2], [6]. SJS and TEN 
are categorized based on the percentage of epidermal 
detachment area: (i) SJS: <10%, (ii) TEN: >30%, and 
(iii) overlapping SJS/TEN: 10–30% [2].
The pathogenesis of SJS/TEN is not fully 
understood, but there are some immunological 
and genetic factors which are believed to be 
involved [4], [5], [7], [8], [9]. There is a strong association 
between HLA-B*15:02 and carbamazepine-induced 
SJS/TEN [10], [11], [12], HLA-B*58:01 and allopurinol-
induced SJS/TEN [13], [14], [15], and HLA-B*57:01 and 
abacavir-induced SJS/TEN [15], [16], [17]. CD8+ cytotoxic 
T cells (CTLs) and natural killer (NK) cells play an important 
role in the pathogenesis of SJS/TEN [1], [4], [5], [8], [9]. The 
immune response may be triggered by binding an antigenic 
drug to a specific HLA on a keratinocyte [4], [5]. Specific T 
cell receptors recognize the drug-HLA complex and upon 
the activation, CD8+CTLs and NK cells produce cytokines, 
chemokines, and cytotoxic proteins, particularly granulysin, 
that cause extensive keratinocytes apoptosis [4], [5]. Chung 
reported that granulysin concentrations in the blister fluid 
of SJS/TEN patients were 2–4 times higher than perforin, 
granzyme B, or soluble Fas ligand concentrations [18]. 
Granulysin in the blister fluid was 15-kDa secretory form, 
and injection of it into mouse skin resulted in features 
mimicking SJS/TEN [5], [18], [19]. Abe showed that 
serum granulysin levels in patients with SJS/TEN were 
elevated before skin detachment or mucosal lesions 
developed [20]. The rapid immunochromatographic test 
has been developed for serum granulysin to diagnose 
early SJS/TEN [21].
Erythema multiforme (EM) may have skin 
manifestation similar to SJS/TEN [2], [22], [23], but they 
can be distinguished immunopathologically. In cases 
of SJS/TEN, the inflammatory infiltrates expressing 
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granulysin, granzyme B, and perforin accumulated 
predominantly in the lower epidermal and subepidermal 
bulla, in contrast, they were relatively sparse in EM [24]. 
However, this test is not clinically rapid. On the other 
hand, serum granulysin levels may be elevated 
among SJS/TEN patients [20], [25]. To the best of 
our knowledge, there is no study compared serum 
granulysin levels in SJS/TEN with those in EM. We 
conducted this study to investigate serum granulysin 
levels in patients with SJS/TEN and EM as well as 
possible associations between serum granulysin levels 
and the severity of SJS/TEN.
Materials and Methods
Participants
SJS/TEN patients
In total, 48 patients with SJS/TEN were enrolled 
from January 2018 to October 2019 at two hospitals 
in Hanoi, Vietnam (National Hospital of Dermato-
venereology and Bach Mai Hospital). The SJS/TEN 
patients had their vital signs and systemic symptoms 
and the percentage of body surface area affected (skin 
detachment) examined. SJS and TEN were classified 
in accordance with Bastuji-Garin et al. [2]. All patients 
were aged 18 or older. The onset was defined as the 
day mucocutaneous or ocular lesions were first eroded 
or ulcerated [20]; the re-epithelialization was defined as 
complete healing of the skin without any erosion [26]. 
The severity of SJS/TEN patients was also assessed 
by the modified-SCORTEN (SCORe of TEN) scale that 
was composed of six well-defined criteria, including age 
>40 years, malignancy, tachycardia>120 beats/min, 
percentage of epidermal detachment >10%, serum 
urea >10 mmol/L, and serum glucose >14 mmol/L. This 
scale was based on SCORTEN scale of Bastuji-Garin 
et al. consisting of seven criteria [27].
EM patients and health controls (HCs)
There were 43 patients with EM recruited in 
this study. They had the presence of typical or atypical 
cutaneous target lesions, with or without mucous 
membrane lesions. The causes of EM were either 
drugs or unknown. Twenty HCs recruited were healthy 
medical staff in the National Hospital of Dermatology 
and Venereology, Ha Noi, Vietnam.
Measuring serum granulysin levels
In the SJS/TEN group, we took blood samples 
at 2-time points (1) at the day of hospitalization and 
(2) at the day of re-epithelialization. In the EM group, 
blood samples were taken at the day of hospitalization. 
All blood samples were left to coagulate at room 
temperature 10–20 min, then centrifuged in 20 min at 
a speed of 2000–000 r.p.m, finally serum was taken 
and stored at −20°C until proceeding the granulysin 
measurement.
Using enzyme-linked immunosorbent assay 
(ELISA) (Human Granulysin ELISA Kit, MELSIN, 
China), we quantified granulysin in all serum samples. 
The kit used ELISA-double antibody sandwich principle 
to assess granulysin levels. The microELISA strip 
plate provided in this kit has been coated by purified 
granulysin antibody to make solid-phase antibody, in 
sequence granulysin is added to wells, combined with 
granulysin antibody labeled by horseradish peroxidase, 
which then becomes an antibody-antigen-enzyme-
antibody complex. After washing completely to remove 
the uncombined enzyme, chromogen solution A and 
chromogen solution B were added, changing the color 
of the liquid to blue which in turn turns into yellow due 
to the effect of acid. The color change was measured 
spectrophotometrically at a wavelength of 450 nm. 
The concentration of granulysin in the samples was 
then determined by comparing the O.D. of the samples 
to the standard curve. The minimum detectable 
dose of granulysin is typically <0.15 ng/ml (following 
manufacturer’s instruction).
Statistical analysis and ethical clearance
Data entry and analysis were conducted by 
using SPSS software version 16.0 (IBM, Armonk, NY, 
USA). The Mann–Whitney U test and Wilcoxon test were 
used to compare quantitative variables. Differences 
were considered to be statistically significant at p < 0.05.
The study was approved by the Ethical Review 
Committee on Research Involving Human Subjects, 
Hanoi Medical University (Number 04NCS17, dated 
February 08, 2018). Written consent was obtained from 
all participants.
Results
There were 19 SJS patients (39.5%) and 29 
TEN patients (60.5%) participating in our study. Their 
characteristics are shown in Table 1. The mean age 
was 49.3, range 19–77 years (47.9% males; 52.1% 
females). The most common causative drugs were 
traditional medicine (29.1%), carbamazepine (12.5%), 
and allopurinol (12.5%). The time between the onset 
and the day of hospitalization was 5.9 ± 2.7 days (range 
2–18 days). The mean body surface area affected was 
43.7%. The mean m-SCORTEN score was 1.6. The 
mean time of re-epithelialization was 15.9 days (range 
9–31 days). All SJS/TEN patients got re-epithelialization 
and total resolution, no one with in-hospital mortality. 
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granulysin levels and the ages with r = (−0.25), but it was 
not statistically significant (p = 0.081) (Figure 3a). There 
was no correlation between serum granulysin levels 
and the body surface area affected (r = 0.12; p = 0.417) 
(Figure 3b); between serum granulysin levels and 
modified-SCORTEN with r = (−0.16), p = 0.29 (Figure 3c). 
Serum granulysin levels were not affected by some 
clinical/paraclinical such as fever, malfunction of kidney, 
pneumonia, high level of liver enzymes, and mucous 
membrane lesion (Figure 4). We had a TEN patient 
whose progress of disease is shown in Figure 5.
Figure 1: Serum granulysin levels of healthy controls, erythema 
multiforme group, and Stevens-Johnson syndrome/toxic epidermal 
necrolysis p > 0.05 group
Discussion
This study showed that serum granulysin 
levels in SJS/TEN patients were statistically higher 
than those in EM patients. There was no significant 
difference with regard to serum granulysin levels in SJS 
and TEN patients. Serum granulysin levels in patients 
hospitalized <6 days of the onset were higher than after 
≥6 days; however, it was not statistically significant.
Granulysin is a cytolytic molecule presenting 
in human CTL and NK cell granules [28] and is 
lytic against a variety of tumor cell targets and 
microbes [28], [29]. In combination with purified perforin, 
recombinant granulysin breaks up 90% of intracellular 
Mycobacterium tuberculosis, inducing lesions on the 
mycobacterial cell surface [29]. Previous studies as 
regards SJS/TEN support the concept that SJS/TEN 
are SCARs initiated by CTLs [5], [8], [18], [30]. It has 
been observed that in patients with SJS/TEN, CTLs, 
and NK cells infiltrate the skin lesions, which point 
to cutaneous recruitment of antigen-primed CTLs in 
the pathogenesis of SJS/TEN [8], [18], [31]. Chung 
demonstrated that SJS/TEN blister cells were, in most 
part, formed by CD8+CTLs, CD56+NK, and NK cells, 
The characteristics of EM patients are shown in Table 2. 
The mean age was 41.4, range 19–76 (30.2% males; 
69.8% females). The medication was responsible for 
41.9% of patients with EM.
Table 1: Characteristics of patients with SJS/TEN
Characteristics SJS (n=19) TEN (n=29) SJS/TEN (n=48)
Age, years 44.9±15.3 52.2±14.3 49.3±15.0
(Range) (19-72) (25-77) (19-77)
Sex, n (%)
Male 11 (57.9) 12 (41.4) 23 (47.9)
Female 8 (42.1) 17 (58.6) 25 (52.1)
Causative drugs, n (%)
Carbamazepine 5 (26.2) 1 (3.4) 6 (12.5)
Allopurinol 4 (21.1) 2 (6.9) 6 (12.5)
Traditional medicine 2 (10.5) 12 (41.5) 14 (29.1)
Antibiotics 1 (5.3) 2 (6.9) 3 (6.2)
NSAIDs 1 (5.3) 3 (10.3) 4 (8.4)
Thalidomide 0 (0) 1 (3.4) 1 (2.1)
Unknown 6 (31.6) 8 (27.6) 14 (29.2)
The time between onset and 
hospitalization, days
5.5 ± 1.6 6.1 ± 3.2 5.9 ± 2.7
Taking corticosteroids before hospitalization, n (%)
Yes 7 (36.8) 13 (44.8) 20 (41.7)
No 8 (42.1) 13 (44.8) 21 (43.7)
Unknown 4 (21.1) 3 (10.4) 7 (14.6)
Body surface area affected, % 7±7.4 67.8±21.7 43.7±34.7
m-SCORTEN score 1±0.9 2±0.7 1.6±0.9
Fever, n (%) 8 (42.1) 19 (65.5) 27 (56.2)
High levels of liver enzymes, n (%) 11 (57.9) 19 (65.5) 30 (62.5)
Malfunction of kidney 6 (31.6) 14 (48.3) 20 (41.7)
Mucous membrane lesions 18 (94.7) 21 (72.4) 39 (81.2)
Pneumonia 0 (0) 8 (27.6) 8 (16.7)
Treatment given during hospitalization, n (%)
Systemic corticoid 16 (84.2) 19 (65.5) 35 (72.9)
Ciclosporin A 3 (15.8) 8 (27.6) 11 (22.9)
Only care support 0 (0) 2 (6.9) 2 (4.2)
The time of re-epithelialization, days 13.8±3.7 17.2±4.6 15.9±4.6
(Range) (9–23) (10–31) (9–31)
SJS: Stevens-Johnson syndrome, TEN: Toxic epidermal necrolysis, NSAIDs: Nonsteroid anti-inflammatory 
drugs, SCORTEN: SCORe of toxic epidermal necrolysis
Table 2: Characteristics of patients with EM and HCs
Characteristics EM (n=43) HCs (n=20)
Age, years 41.4±17.3 28.4±3.5
(range) (19–76) (25–37)
Sex, n (%)
Male 13 (30.2) 10 (50)
Female 30 (69.8) 10 (50)
Causes, n (%) NA
Medication 18 (41.9)
Traditional medicine 8 (44.4)
Antibiotics 5 (27.8)
Allopurinol 3 (16.6)
Herbal food 2 (11.2)
Unknown 25 (58.1)
Cutaneous lesions, n (%) NA
Typical targets 7 (16.3)
Atypical targets 30 (69.7)
Both typical and atypical targets 6 (14)
Mucous membrane lesion, n (%) 9 (20.9) NA
Fever, n (%) 10 (23.3) NA
EM: Erythema multiforme, HCs: Healthy controls, NA: Not applicable.
Serum granulysin levels of patients with 
SJS/TEN (23.0 ng/ml; range 1.2–144.6 ng/ml) were 
significantly higher than those of patients with EM (20.1 
ng/ml; range 8.5–121 ng/ml; p < 0.05) and those of HCs 
(20.8 ng/ml; range 10.1–46.7 ng/ml; p < 0.05) (Figure 1). 
There was no significant difference with regard to serum 
granulysin levels among SJS and TEN patients (21.7 
ng/ml versus 23.9 ng/ml; p > 0.05) (Figure 2a). In the 
SJS/TEN group, serum granulysin levels were higher 
in the 25 samples collected <6 days of the onset (27.7 
ng/ml; range 2.5–144.6 ng/ml) than in the 23 samples 
collected ≥6 days after the onset (17.9 ng/ml; range 
1.2–59 ng/ml) but it was not significantly different 
(p > 0.05) (Figure 2b). Serum granulysin levels were 
not significantly different between male and female 
patients with SJS/TEN (Figure 2c). In patients with SJS/
TEN, there was a negative correlation between serum 
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and these effector cells showed cytotoxicity against 
target cells [18]. These findings are favorable to the key 
role of granulysin, a product of CTLs and NK cells, in 
the pathogenesis of SJS/TEN.
EM is a cutaneous reaction characterized by 
typical or atypical target lesions that mimic cutaneous 
manifestations of SJS/TEN in the early phase [2], [22], [23]. 
The causes of EM may be a viral infection or drug reaction 
[22], [23], [32]. Serum granulysin can be also elevated in 
viral infected conditions [33] such as virus-associated EM. 
Nevertheless, our results may imply the use of serum 
granulysin as a biomarker for distinguishing between EM 
and SJS/TEN. In fact, serum granulysin levels can be 
affected by some factors such as infection [33], [34], [35], 
sepsis [36], cancers [34], [37], age [33], and immunological 
condition [35], hence, it was a large range among our SJS/
TEN patients. However, systemic corticosteroid treatment 
before hospitalization did not affect serum granulysin 
levels in patients with SJS/TEN.
In the present study, there was no association 
between serum granulysin levels and some clinical/
paraclinical manifestations of SJS/TEN. At the day of 
re-epithelialization, serum granulysin levels were not 
significantly different compared with those at the day of 
being hospitalized. These findings could be explained 
by the fact that nearly all the 48 patients with SJS/TEN 
in this study had their serum granulysin measured after 
the onset (mean 5.9 days) when serum granulysin levels 
could be decreased. Abe et al. showed that in SJS/TEN, 
serum granulysin levels were elevated before the onset 
(when skin detachment or mucosal lesion develop) and 
higher than those of ordinary drug-induced skin reactions 
[20]. However, the mean level of serum granulysin in 
this study was consistent with that in Abe’s et al. study 
(24.8 ng/ml) [20]. It could be due to the difference in the 
size of samples in each study.
By using the sandwich ELISA method, a study in 
Japan shows the mean level of serum granulysin among 
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Figure 2: Comparison of serum granulysin levels (ng/ml) in SJS/TEN: Between SJS and TEN (a); the 25 samples collected <6 days of the onset 
and the 23 samples collected ≥6 days after the onset (b); male and female patients (c); At the day of hospitalization and re-epithelialization (d). 
SJS: Stevens-Johnson syndrome; TEN: toxic epidermal necrolysis
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Figure 4: Serum granulysin levels (ng/ml) and some clinical/paraclinical in patients with SJS/TEN; *p > 0.05. SJS: Stevens-Johnson syndrome; 
TEN: Toxic epidermal necrolysis
Figure 3: Correlation between serum granulysin levels in SJS/TEN patients and the ages (a), the body surface area affected (b), the modified-
SCORTEN (c). SJS: Stevens-Johnson syndrome; TEN: Toxic epidermal necrolysis; SCORTEN: SCORe of toxic epidermal necrolysis
a b
c
healthy individuals is 3.7 ng/ml, and it also demonstrates 
a positive correlation between serum granulysin 
levels and age, but no significant difference in serum 
granulysin levels between genders [33]. Furthermore, 
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a study among health staffs from tuberculosis hospitals 
in Hanoi, Vietnam, also shows lower levels of serum 
granulysin as compared with those of the present 
study [35]. This may be due to the difference in study 
populations, age, and immunological conditions. On 
the other hand, HCs in our study were medical staff, 
who possibly have higher chances of being exposed 
to bacterial or viral infections in hospital environments.
Cho et al. showed that the serum level of 
granulysin of patients with generalized bullous fixed 
drug eruption (GBFDE) was significantly lower than 
that of patients with SJS/TEN overlap or TEN [25]. 
In GBFDE, granulysin is mainly produced by NK 
cells, whilst in SJS/TEN both NK cells and CTLs 
play an essential role. The presence of granulysin 
in lesional skin and in serum is a principal factor to 
distinguish GBFDE from SJS/TEN [25]. Furthermore, 
serum granulysin levels are not elevated exclusively 
in SJS/TEN; other conditions have also shown to be 
responsible for high serum granulysin levels, such 
as graft-versus-host disease [33], [38], drug reaction 
with eosinophilia and systemic symptoms, or drug-
induced hypersensitivity syndrome [39]. Another study 
in Taiwan shows that high plasma granulysin levels 
were associated with renal impairment and mortality 
rates of patients with allopurinol-induced SJS/TEN [14]. 
Deceased patients showed higher concentrations of 
granulysin for extended periods of time when compared 
to the survivors [14]. Su et al. demonstrated that the 
levels of interleukin-15 and granulysin were significantly 
correlated with the disease extension in SJS/TEN [36]. 
These studies implied that serum granulysin levels may 
be used as a biomarker for not only the diagnosis but 
also the prognosis of SCARs. However, in our study, 
after the onset of SJS/TEN, serum granulysin level is 
not useful for evaluating the severity of SJS/TEN.
This study had some limitations. First, we 
collected serum samples several days after the onset of 
SJS/TEN when serum granulysin levels might have been 
decreased a lot. Second, HCs group were healthy health 
staffs whose serum granulysin levels might be higher than 
those of the general population. Third, we only measured 
granulysin levels in sera and were not able to quantify them 
in blister fluids and identify the presence of granulysin on 
skin tissue. Fourth, we did not identify the cells secreting 
granulysin. In fact, there are other cytotoxic proteins and 
molecules such as perforin, granzyme B [5], [18], [40], 
and annexin A1 [41] relating to the pathogenesis of SJS/
TEN but we could not investigate all of them. Finally, we 
used modified-SCORTEN as serum bicarbonate test was 
not available in the study settings. However, the mean 
m-SCORTEN in this study was consistent with the mean 
SCORTEN of a previous study in Vietnam [11].
Conclusion
Serum granulysin levels are significantly higher 
in SJS/TEN patients than in EM patients. After the onset 
of SJS/TEN, serum granulysin is not associated with 
the severity of the diseases.
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